세계의 항생제 내성(AMR) 진단 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for antimicrobial resistance (AMR) diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global AMR diagnostics market from 2025 to 2032.

Key Insights:

• AMR Diagnostics Market Size (2025E): USD 4,830.7 Million
• Projected Market Value (2032F): USD 7,620.1 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 6.7%

AMR Diagnostics Market - Report Scope:

Antimicrobial resistance (AMR) diagnostics play a crucial role in detecting and addressing antibiotic resistance in microbial pathogens. These diagnostics are vital for accurate identification and treatment of resistant infections, which is critical in preventing the misuse of antibiotics and promoting effective treatment regimens. The AMR diagnostics market serves hospitals, diagnostic centers, and clinics, offering a range of diagnostic tools including molecular diagnostics, culture-based methods, and rapid diagnostic tests. Market growth is driven by the increasing prevalence of drug-resistant infections, rising awareness of AMR, and the growing need for personalized medicine to improve treatment outcomes.

Market Growth Drivers:

The global AMR diagnostics market is driven by several key factors, including the escalating prevalence of antimicrobial-resistant infections worldwide. As resistant pathogens continue to emerge, healthcare providers face significant challenges in treating infections effectively, which propels the demand for accurate and rapid diagnostics. Additionally, the increasing investment in R&D and the development of advanced diagnostic tools, such as next-generation sequencing and multiplex PCR tests, is boosting market expansion. The rising government and healthcare agency support for AMR awareness programs and the integration of AMR diagnostic solutions into clinical practice further contribute to market growth. Furthermore, the growing emphasis on antimicrobial stewardship programs and improved infection control measures is expected to accelerate the adoption of AMR diagnostics.

Market Restraints:

Despite promising growth prospects, the AMR diagnostics market faces challenges related to high costs and limited reimbursement for certain diagnostic tests, particularly in emerging economies. Regulatory hurdles, such as lengthy approval processes for new diagnostic technologies and compliance with international standards, can also slow market entry. Moreover, the complexity of developing diagnostic tools that accurately identify resistant strains of pathogens across diverse patient populations presents technical challenges. These factors create barriers to the widespread adoption of AMR diagnostics, particularly in regions with limited healthcare infrastructure.

Market Opportunities:

The AMR diagnostics market presents significant growth opportunities driven by advancements in molecular diagnostics, AI-powered diagnostic tools, and real-time data analysis. The integration of artificial intelligence and machine learning into diagnostic platforms enables faster and more accurate detection of resistant pathogens, creating new avenues for market expansion. Additionally, the increasing focus on personalized medicine and precision healthcare provides opportunities for tailored diagnostic solutions to improve treatment outcomes. Partnerships between diagnostic companies, healthcare providers, and government agencies will help overcome barriers to access and expand the availability of AMR diagnostic tools across global healthcare settings.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the AMR diagnostics market globally?
• Which diagnostic methods and technologies are most widely adopted across healthcare settings?
• How are technological advancements reshaping the competitive landscape of the AMR diagnostics market?
• Who are the key players contributing to the AMR diagnostics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global AMR diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global AMR diagnostics market, including Roche Diagnostics, Abbott Laboratories, BioMerieux, and Cepheid, focus on innovation, product differentiation, and strategic partnerships to maintain their competitive edge. These companies invest in R&D to develop advanced diagnostic technologies such as next-generation sequencing, CRISPR-based diagnostics, and multiplex PCR tests. Collaborations with healthcare providers, academic institutions, and regulatory agencies are essential for accelerating the adoption of AMR diagnostics and ensuring compliance with evolving global standards. Additionally, increased focus on patient education and AMR awareness initiatives supports the market growth and enhances the effectiveness of diagnostic tools in combating antimicrobial resistance.

Key Companies Profiled:

• Abbott Laboratories
• Accelerated Diagnostics, USA
• Alifax
• Bio-Rad Laboratories
• BioMerieux
• Beckman Coulter
• Becton, Dickinson and Company
• F.Hoffmann-La Roche
• Molsid
• Thermo Fisher Scientific
• Vela Diagnostics
• Others

AMR Diagnostics Market Research Segmentation:

The AMR diagnostics market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various clinical needs and patient populations.

By Product Type

• Instruments
• Reagents & Consumables

By Technology

• Polymerase Chain Reaction (PCR)
• Microbiology Culture
• Immunoassay
• Next-generation sequencing (NGS)
• Mass Spectrometry
• Point-of-care
• Others

By Pathogen Type

• Methicillin-resistant Staphylococcus aureus (MRSA)
• Drug-resistant Streptococcus pneumoniae (DRSP)
• Drug-resistant Campylobacter (DRC)
• Clostridium difficile (CD)
• Drug-resistant Neisseria gonorrhoeae (DRNG)
• Others

By End-user

• Hospitals & Clinics
• Diagnostics Laboratories
• Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Antimicrobial Resistance Diagnostics Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Type Adoption Analysis
• 3.3. Technological Advancements
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Antimicrobial Resistance Diagnostics Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Antimicrobial Resistance Diagnostics Market Outlook: Product Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 4.3.3.1. Instruments
    • 4.3.3.2. Reagents & Consumables
  • 4.3.4. Market Attractiveness Analysis: Product Type
• 4.4. Global Antimicrobial Resistance Diagnostics Market Outlook: Technology
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Technology, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 4.4.3.1. Polymerase Chain Reaction (PCR)
    • 4.4.3.2. Microbiology Culture
    • 4.4.3.3. Immunoassay
    • 4.4.3.4. Next-Generation Sequencing (NGS)
    • 4.4.3.5. Mass Spectrometry
    • 4.4.3.6. Point-of-care
    • 4.4.3.7. Others
  • 4.4.4. Market Attractiveness Analysis: Technology
• 4.5. Global Antimicrobial Resistance Diagnostics Market Outlook: Pathogen Type
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Pathogen Type, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
    • 4.5.3.1. Methicillin-resistant Staphylococcus aureus (MRSA)
    • 4.5.3.2. Drug-resistant Streptococcus pneumoniae (DRSP)
    • 4.5.3.3. Drug-resistant Campylobacter (DRC)
    • 4.5.3.4. Clostridium difficile (CD)
    • 4.5.3.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
    • 4.5.3.6. Others
  • 4.5.4. Market Attractiveness Analysis: Pathogen Type
• 4.6. Global Antimicrobial Resistance Diagnostics Market Outlook: End-user
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
    • 4.6.3.1. Hospitals & Clinics
    • 4.6.3.2. Diagnostics Laboratories
    • 4.6.3.3. Research Institutes
    • 4.6.3.4. Pharmaceutical & Biotechnology Companies
    • 4.6.3.5. Others
  • 4.6.4. Market Attractiveness Analysis: End-user

5. Global Antimicrobial Resistance Diagnostics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Antimicrobial Resistance Diagnostics Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product Type
  • 6.2.3. By Technology
  • 6.2.4. By Pathogen Type
  • 6.2.5. By End-user
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
  • 6.4.1. Instruments
  • 6.4.2. Reagents & Consumables
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 6.5.1. Polymerase Chain Reaction (PCR)
  • 6.5.2. Microbiology Culture
  • 6.5.3. Immunoassay
  • 6.5.4. Next-Generation Sequencing (NGS)
  • 6.5.5. Mass Spectrometry
  • 6.5.6. Point-of-care
  • 6.5.7. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
  • 6.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
  • 6.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
  • 6.6.3. Drug-resistant Campylobacter (DRC)
  • 6.6.4. Clostridium difficile (CD)
  • 6.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
  • 6.6.6. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  • 6.7.1. Hospitals & Clinics
  • 6.7.2. Diagnostics Laboratories
  • 6.7.3. Research Institutes
  • 6.7.4. Pharmaceutical & Biotechnology Companies
  • 6.7.5. Others
• 6.8. Market Attractiveness Analysis

7. Europe Antimicrobial Resistance Diagnostics Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product Type
  • 7.2.3. By Technology
  • 7.2.4. By Pathogen Type
  • 7.2.5. By End-user
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
  • 7.4.1. Instruments
  • 7.4.2. Reagents & Consumables
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 7.5.1. Polymerase Chain Reaction (PCR)
  • 7.5.2. Microbiology Culture
  • 7.5.3. Immunoassay
  • 7.5.4. Next-Generation Sequencing (NGS)
  • 7.5.5. Mass Spectrometry
  • 7.5.6. Point-of-care
  • 7.5.7. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
  • 7.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
  • 7.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
  • 7.6.3. Drug-resistant Campylobacter (DRC)
  • 7.6.4. Clostridium difficile (CD)
  • 7.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
  • 7.6.6. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  • 7.7.1. Hospitals & Clinics
  • 7.7.2. Diagnostics Laboratories
  • 7.7.3. Research Institutes
  • 7.7.4. Pharmaceutical & Biotechnology Companies
  • 7.7.5. Others
• 7.8. Market Attractiveness Analysis

8. East Asia Antimicrobial Resistance Diagnostics Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product Type
  • 8.2.3. By Technology
  • 8.2.4. By Pathogen Type
  • 8.2.5. By End-user
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
  • 8.4.1. Instruments
  • 8.4.2. Reagents & Consumables
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 8.5.1. Polymerase Chain Reaction (PCR)
  • 8.5.2. Microbiology Culture
  • 8.5.3. Immunoassay
  • 8.5.4. Next-Generation Sequencing (NGS)
  • 8.5.5. Mass Spectrometry
  • 8.5.6. Point-of-care
  • 8.5.7. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
  • 8.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
  • 8.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
  • 8.6.3. Drug-resistant Campylobacter (DRC)
  • 8.6.4. Clostridium difficile (CD)
  • 8.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
  • 8.6.6. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  • 8.7.1. Hospitals & Clinics
  • 8.7.2. Diagnostics Laboratories
  • 8.7.3. Research Institutes
  • 8.7.4. Pharmaceutical & Biotechnology Companies
  • 8.7.5. Others
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Antimicrobial Resistance Diagnostics Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product Type
  • 9.2.3. By Technology
  • 9.2.4. By Pathogen Type
  • 9.2.5. By End-user
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
  • 9.4.1. Instruments
  • 9.4.2. Reagents & Consumables
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 9.5.1. Polymerase Chain Reaction (PCR)
  • 9.5.2. Microbiology Culture
  • 9.5.3. Immunoassay
  • 9.5.4. Next-Generation Sequencing (NGS)
  • 9.5.5. Mass Spectrometry
  • 9.5.6. Point-of-care
  • 9.5.7. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
  • 9.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
  • 9.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
  • 9.6.3. Drug-resistant Campylobacter (DRC)
  • 9.6.4. Clostridium difficile (CD)
  • 9.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
  • 9.6.6. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  • 9.7.1. Hospitals & Clinics
  • 9.7.2. Diagnostics Laboratories
  • 9.7.3. Research Institutes
  • 9.7.4. Pharmaceutical & Biotechnology Companies
  • 9.7.5. Others
• 9.8. Market Attractiveness Analysis

10. Latin America Antimicrobial Resistance Diagnostics Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product Type
  • 10.2.3. By Technology
  • 10.2.4. By Pathogen Type
  • 10.2.5. By End-user
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
  • 10.4.1. Instruments
  • 10.4.2. Reagents & Consumables
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 10.5.1. Polymerase Chain Reaction (PCR)
  • 10.5.2. Microbiology Culture
  • 10.5.3. Immunoassay
  • 10.5.4. Next-Generation Sequencing (NGS)
  • 10.5.5. Mass Spectrometry
  • 10.5.6. Point-of-care
  • 10.5.7. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
  • 10.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
  • 10.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
  • 10.6.3. Drug-resistant Campylobacter (DRC)
  • 10.6.4. Clostridium difficile (CD)
  • 10.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
  • 10.6.6. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  • 10.7.1. Hospitals & Clinics
  • 10.7.2. Diagnostics Laboratories
  • 10.7.3. Research Institutes
  • 10.7.4. Pharmaceutical & Biotechnology Companies
  • 10.7.5. Others
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Antimicrobial Resistance Diagnostics Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product Type
  • 11.2.3. By Technology
  • 11.2.4. By Pathogen Type
  • 11.2.5. By End-user
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
  • 11.4.1. Instruments
  • 11.4.2. Reagents & Consumables
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 11.5.1. Polymerase Chain Reaction (PCR)
  • 11.5.2. Microbiology Culture
  • 11.5.3. Immunoassay
  • 11.5.4. Next-Generation Sequencing (NGS)
  • 11.5.5. Mass Spectrometry
  • 11.5.6. Point-of-care
  • 11.5.7. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
  • 11.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
  • 11.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
  • 11.6.3. Drug-resistant Campylobacter (DRC)
  • 11.6.4. Clostridium difficile (CD)
  • 11.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
  • 11.6.6. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  • 11.7.1. Hospitals & Clinics
  • 11.7.2. Diagnostics Laboratories
  • 11.7.3. Research Institutes
  • 11.7.4. Pharmaceutical & Biotechnology Companies
  • 11.7.5. Others
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. bioMerieux
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Product Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Roche Diagnostics
  • 12.3.3. Cepheid
  • 12.3.4. Hologic, Inc.
  • 12.3.5. Thermo Fisher Scientific
  • 12.3.6. Illumina, Inc.
  • 12.3.7. Oxford Nanopore Technologies
  • 12.3.8. Pacific Biosciences (PacBio)
  • 12.3.9. Qiagen
  • 12.3.10. Agilent Technologies
  • 12.3.11. Randox Laboratories
  • 12.3.12. Bruker Corporation
  • 12.3.13. Becton, Dickinson and Company (BD)
  • 12.3.14. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations